FRAILOMIC
"Utility of omic-based biomarkers in characterizing older individuals at risk for frailty, its progression to disability and general consequences to health and well-being - The FRAILOMIC Initiative"
| Coordinatore | SERVICIO MADRILENO DE SALUD
Organization address
address: PLAZA CARLOS TRIAS BERTRAN 7 contact info |
| Nazionalità Coordinatore | Spain [ES] |
| Totale costo | 15˙251˙106 € |
| EC contributo | 11˙940˙343 € |
| Programma | FP7-HEALTH
Specific Programme "Cooperation": Health |
| Code Call | FP7-HEALTH-2012-INNOVATION-1 |
| Funding Scheme | CP-IP |
| Anno di inizio | 2013 |
| Periodo (anno-mese-giorno) | 2013-01-01 - 2017-12-31 |
Partecipanti
| # | ||||
|---|---|---|---|---|
| 1 |
SERVICIO MADRILENO DE SALUD
Organization address
address: PLAZA CARLOS TRIAS BERTRAN 7 contact info |
ES (MADRID) | coordinator | 1˙571˙910.00 |
| 2 |
YH YOUHEALTH AB
Organization address
address: FOGDEVRETEN 2 KAROLINSKA SCIENCE contact info |
SE (STOCKHOLM) | participant | 922˙400.00 |
| 3 |
LIFE LENGTH SL
Organization address
address: CALLE AGUSTIN DE BETANCOURT 21 contact info |
ES (MADRID) | participant | 831˙760.00 |
| 4 |
SISTEMAS GENOMICOS SL
Organization address
address: RONDA G MARCONI - PARQUE TECNOLOGICO DE VALENCIA 6 contact info |
ES (PATERNA) | participant | 824˙670.00 |
| 5 |
WORLD HEALTH ORGANIZATION.
Organization address
address: Avenue Appia 20 contact info |
CH (GENEVE) | participant | 742˙350.00 |
| 6 |
MOSAIQUES DIAGNOSTICS GMBH
Organization address
address: Mellendorfer Strasse 7-9 contact info |
DE (HANNOVER) | participant | 599˙888.40 |
| 7 |
UNIVERSITAT DE VALENCIA
Organization address
address: AVENIDA BLASCO IBANEZ 13 contact info |
ES (VALENCIA) | participant | 596˙520.00 |
| 8 |
EVERCYTE GMBH
Organization address
address: MUTHGASSE 18 contact info |
AT (WIEN) | participant | 592˙222.00 |
| 9 |
UNIVERSIDAD AUTONOMA DE MADRID
Organization address
address: CALLE EINSTEIN, CIUDAD UNIV CANTOBLANCO RECTORADO 3 contact info |
ES (MADRID) | participant | 586˙090.00 |
| 10 |
UNIVERSITAET INNSBRUCK
Organization address
address: INNRAIN 52 contact info |
AT (INNSBRUCK) | participant | 546˙598.44 |
| 11 |
FRIEDRICH-SCHILLER-UNIVERSITAT JENA
Organization address
address: FURSTENGRABEN 1 contact info |
DE (JENA) | participant | 505˙080.00 |
| 12 |
AZIENDA SANITARIA DI FIRENZE
Organization address
address: PIAZZA SANTA MARIA NUOVA 1 contact info |
IT (FIRENZE) | participant | 447˙010.00 |
| 13 |
UNIVERSITY OF BEDFORDSHIRE
Organization address
address: PARK SQUARE contact info |
UK (LUTON) | participant | 442˙400.00 |
| 14 |
CARDIFF METROPOLITAN UNIVERSITY
Organization address
address: Llandaff Campus western Avenue contact info |
UK (Cardiff) | participant | 441˙612.60 |
| 15 |
AZIENDA OSPEDALIERO-UNIVERSITARIA DI PARMA
Organization address
address: VIA GRAMSCI 14 contact info |
IT (PARMA) | participant | 440˙500.00 |
| 16 |
INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM)
Organization address
address: 101 Rue de Tolbiac contact info |
FR (PARIS) | participant | 419˙142.00 |
| 17 |
UNIVERSITE DE BORDEAUX
Organization address
address: PLACE PEY BERLAND 35 contact info |
FR (BORDEAUX) | participant | 344˙500.00 |
| 18 |
NICHE SCIENCE & TECHNOLOGY LTD
Organization address
address: WOLSEY DRIVE 96 contact info |
UK (KINGSTON UPON THAMES) | participant | 263˙200.00 |
| 19 |
INNOVACION DESARROLLO Y TRANSFERENCIA DE TECNOLOGIA SA
Organization address
address: CALLE HERMOSILLA 48-3 IZQ contact info |
ES (Madrid) | participant | 260˙600.00 |
| 20 |
CONSIGLIO NAZIONALE DELLE RICERCHE
Organization address
address: Piazzale Aldo Moro 7 contact info |
IT (ROMA) | participant | 254˙375.00 |
| 21 |
CENTRE HOSPITALIER UNIVERSITAIRE DE TOULOUSE
Organization address
address: "Rue Viguerie, Hotel-Dieu Saint Jacques 2" contact info |
FR (TOULOUSE) | participant | 177˙200.00 |
| 22 |
SAN RAFFAELE S.p.A.
Organization address
address: VIA DI VAL CANNUTA 247 contact info |
IT (ROMA) | participant | 130˙315.00 |
| 23 |
ISTITUTO NAZIONALE DI RIPOSO E CURA PER ANZIANI INRCA
Organization address
address: Via Santa Margherita 5 contact info |
IT (ANCONA) | participant | 0.00 |
Mappa
Word cloud
Esplora la "nuvola delle parole (Word Cloud) per avere un'idea di massima del progetto.
Obiettivo del progetto (Objective)
'The forecasted increase in the number of older people for this century will be accompanied by an increase of those with disabilities. Disability is usually preceded by a condition named frailty that encompasses changes associated with ageing, life styles and chronic diseases. To detect and intervene on it is of outstanding importance to prevent disability, as recovery from disability is unlikely. Recent documents stress the necessity of testing the clinical utility (in terms of risk prediction, diagnosis validity and prognostic significance) of the existing definition of frailty by using combinations of clinical criteria (current definition) and lab Biomarkers (BMs). We will measure the levels of blood and urine omic-based BMs in old people selected from eight cohorts, which include up to 75,000 participants, using standardized and innovative technology (WP1). This figure will allow us to test the research questions with a high power and validity. Combining these lab BMs with clinical BMs, we will develop predictive, diagnostic and prognostic models (WP2), with its modulation by nutrition and physical activity, in general old population and in old people showing some characteristics that confer a high risk for developing frailty (selected cardiovascular risk factors and diseases) (WP4). After that, a selected set of BMs will be validated prospectively (WP3) and assessed to find the best-fitted models (WP4). These models will guide the development of the ready-to-use kits to be implemented in the clinical settings. These kits will be at the center of dissemination and exploitation activities (WP5, WP6). A well-balanced consortium distributed over the individual tasks in the respective work packages will carry it out, with a strong participation of SMEs. In summary, FRAILOMIC is original, relevant, pertinent, feasible, overcome the usual research bottlenecks on Biomarkers, and fits perfectly with the topics addressed by the HEALTH.2012.2.1.1-2 call in human subjects'